Search
Enovis Corp
ENOVAdd to Watchlist
21.700USD
+1.660+8.28%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
1.25BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
+8.28%
5 Days
+1.50%
1 Month
0.00%
6 Months
-18.54%
Year to Date
-18.54%
1 Year
-34.28%
Key Figures
20.610Open
21.750High
453.68KVolume
LossP/E TTM
5.22P/E Dynamic
--Dividend TTM
0.79%Turnover Ratio
20.040Prev. Close
20.230Low
5.91MTurnover
LossP/E Static
0.85P/B
0.00%Div Yield TTM
-26.06%ROA
38.19052wk High
0.55Volume Ratio
-825.49MNet Profit
57.55MShares
-19.9221EPS TTM
1.23Beta
-55.46%ROE
21.00052wk Low
7.58%Amplitude
54.92%Gross Margin
1.25BMarket Cap
-2.68Reward/Risk
3.23%Risk Rate
TradingKey Stock Score of Enovis Corp
Currency: USD Updated: 2026-07-01Key Insights
Enovis Corp's fundamentals are relatively stable, and its growth potential is high.Its valuation is considered fairly valued, ranking 65 out of 204 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 42.30.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Enovis Corp's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Enovis Corp Highlights
StrengthsRisks
Enovis Corporation is a medical technology company. It is focused on developing clinically differentiated solutions by manufacturing and distributing high-quality medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. It operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative diseases. The Prevention & Recovery products are marketed under several brand names, such as DJO. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. It also operates a Enovis Growth eXcellence business system (EGX).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 31.68% year-on-year.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 2.25B.
Overvalued
The company’s latest PE is -1.01, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 68.97M shares, decreasing 8.93% quarter-over-quarter.
Held by Mason Hawkins
Star Investor Mason Hawkins holds 43.70K shares of this stock.
Analyst Rating
Based on
11
analysts
Buy
Current Rating
42.300
Target Price
+104.35%
Upside Space
Enovis Corp News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Enovis Corp Info
Enovis Corporation is a medical technology company. It is focused on developing clinically differentiated solutions by manufacturing and distributing high-quality medical devices with a range of products used for reconstructive surgery, rehabilitation, pain management and physical therapy. It operates through two segments: Prevention & Recovery and Reconstructive. The Prevention & Recovery segment provides orthopedic and recovery science solutions, including devices, software, and services across the patient care continuum from injury prevention to rehabilitation after surgery, injury, or from degenerative diseases. The Prevention & Recovery products are marketed under several brand names, such as DJO. The Reconstructive segment provides surgical implant solutions, offering a comprehensive suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger and surgical productivity tools. It also operates a Enovis Growth eXcellence business system (EGX).
Ticker SymbolENOV
CompanyEnovis Corp
CEOMcdonald (Damien)
Websitehttps://www.enovis.com/
Related Instruments
-0.47%
+2.14%
+3.75%
+4.88%
+1.94%
-1.15%
+4.36%
+4.28%
+5.65%
-0.07%
+1.59%
+6.00%
+1.33%
+2.31%
-2.91%
+2.48%
+2.63%
-0.52%
-0.58%
-0.95%Popular Instruments
52679.900
+425.600 (+0.81%)
29248.800
-550.500 (-1.85%)
7458.600
-16.900 (-0.23%)
14732.000
-623.000 (-4.06%)
67864.000
-1621.000 (-2.33%)
6338.900
+63.500 (+1.01%)
68.534
+0.566 (+0.83%)
308.310
+13.930 (+4.73%)
193.510
-4.070 (-2.06%)
4124.280
+93.510 (+2.32%)
FAQs
What is the current price of Enovis Corp (ENOV)?
The current price of Enovis Corp (ENOV) is 20.03.
What is the symbol of Enovis Corp?
The ticker symbol of Enovis Corp is ENOV.
What is the 52-week high of Enovis Corp?
The 52-week high of Enovis Corp is 38.19.
What is the 52-week low of Enovis Corp?
The 52-week low of Enovis Corp is 21.00.
What is the market capitalization of Enovis Corp?
The market capitalization of Enovis Corp is 1.15B.
Is Enovis Corp (ENOV) currently rated as Buy, Hold, or Sell?
According to analysts, Enovis Corp (ENOV) has an overall rating of Buy, with a price target of 42.30.
What is the Earnings Per Share (EPS TTM) of Enovis Corp (ENOV)?
The Earnings Per Share (EPS TTM) of Enovis Corp (ENOV) is -20.75.